BCL11A

Chr 2

BCL11 transcription factor A

Also known as: CTIP1, DILOS, EVI9, HBFQTL5, SMARCM1, ZNF856

This gene encodes a C2H2 type zinc-finger protein by its similarity to the mouse Bcl11a/Evi9 protein. The corresponding mouse gene is a common site of retroviral integration in myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6. During hematopoietic cell differentiation, this gene is down-regulated. It is possibly involved in lymphoma pathogenesis since translocations associated with B-cell malignancies also deregulates its expression. Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

UniProtIntellectual developmental disorder with persistence of fetal hemoglobin
343
ClinVar variants
116
Pathogenic / LP
0.97
pLI score· haploinsufficient
12
Active trials
Clinical SummaryBCL11A
🧬
Gene-Disease Validity (ClinGen)
Dias-Logan syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.97). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
116 Pathogenic / Likely Pathogenic· 172 VUS of 343 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.32LOEUF
pLI 0.970
Z-score 3.98
OE 0.12 (0.060.32)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.84Z-score
OE missense 0.54 (0.490.59)
296 obs / 548.8 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.12 (0.060.32)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.54 (0.490.59)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.83
01.21.6
LoF obs/exp: 3 / 24.1Missense obs/exp: 296 / 548.8Syn Z: 2.10

ClinVar Variant Classifications

343 submitted variants in ClinVar

Classification Summary

Pathogenic66
Likely Pathogenic50
VUS172
Likely Benign38
Benign12
Conflicting5
66
Pathogenic
50
Likely Pathogenic
172
VUS
38
Likely Benign
12
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
29
7
29
1
66
Likely Pathogenic
27
9
14
0
50
VUS
2
146
19
5
172
Likely Benign
0
11
0
27
38
Benign
0
3
5
4
12
Conflicting
5
Total581766737343

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

BCL11A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

BCL11A-related intellectual disability

definitive
ADLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype

No OMIM entries found.

📖
GeneReview available — BCL11A
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Sickle Cell Anemia and Its Phenotypes.
Williams TN et al.·Annu Rev Genomics Hum Genet
2018Review
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M et al.·N Engl J Med
2017
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

RECRUITING
NCT01238250Simons SearchlightStarted 2010-10
Sickle Cell Disease

A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

ACTIVE NOT RECRUITING
NCT05353647Phase PHASE2David WilliamsStarted 2022-07-12
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Fetal HemoglobinThalassemia MajorGenetic Disease

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

RECRUITING
NCT06490627Phase PHASE2National Institute of Blood and Marrow Transplant (NIBMT), PakistanStarted 2024-04-22
ThalidomideThalidomide
Sickle Cell DiseaseSickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Beta-Thalassemia

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

RECRUITING
NCT06647979Phase PHASE1Daniel BauerStarted 2025-12-01
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoproteinSequencing Assay for Variant rs114518452
Beta-Thalassemia

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

ENROLLING BY INVITATION
NCT05577312Phase PHASE1, PHASE2Bioray LaboratoriesStarted 2022-11-01
BRL-101
Beta-ThalassemiaThalassemiaHematologic Diseases

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

RECRUITING
NCT05477563Phase PHASE3Vertex Pharmaceuticals IncorporatedStarted 2022-08-02
CTX001
Sickle Cell DiseaseHydroxyurea FailureHydroxyurea Intolerance

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

ACTIVE NOT RECRUITING
NCT05329649Phase PHASE3Vertex Pharmaceuticals IncorporatedStarted 2022-05-02
CTX001
Sickle Cell Disease

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

NOT YET RECRUITING
NCT06287086Phase NABioray LaboratoriesStarted 2024-06-14
BRL-101 autologous hematopoietic stem and progenitor cells injection
Beta-ThalassemiaThalassemiaGenetic Diseases, Inborn

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

ACTIVE NOT RECRUITING
NCT05356195Phase PHASE3Vertex Pharmaceuticals IncorporatedStarted 2022-05-03
CTX001
Sickle Cell Disease

Gene Transfer for Sickle Cell Disease

ACTIVE NOT RECRUITING
NCT03282656Phase PHASE1David WilliamsStarted 2018-02-13
single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
Sickle Cell Disease

Clinical Study of BRL-101 in Severe SCD

ENROLLING BY INVITATION
NCT06300723Phase NABioray LaboratoriesStarted 2024-07-29
BRL-101
Sickle Cell Disease

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

ACTIVE NOT RECRUITING
NCT06155500Phase PHASE1Novartis PharmaceuticalsStarted 2024-04-16
OTQ923